文献速递白血病

β-连环蛋白与Bcr-Abl联合抑制在体外和体内协同靶向酪氨酸激酶抑制剂耐药的急变期慢性髓系白血病原始细胞与祖细胞

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
PubMed 文献 · Leukemia · 2017-03-21

研究在急变期慢性髓系白血病(BC-CML)中观察到β-连环蛋白在干细胞/祖细胞(尤其粒-巨噬祖细胞及CD34+CD38+CD123hiTim-3hi亚群)过表达,间充质基质细胞共培养可诱导β-连环蛋白及其靶点CD44表达。Wnt/β-连环蛋白信号调节剂C82与尼洛替尼联用可协同杀伤TKI耐药的原代BC-CML细胞,PRI-724联合尼洛替尼可延长小鼠生存,提示联合抑制β-连环蛋白与Bcr-Abl可能获益。

要点

  • BC-CML干细胞/祖细胞中β-连环蛋白过表达,粒-巨噬祖细胞中尤为明显。
  • C82与尼洛替尼联用可协同杀伤伴或不伴BCR-ABL激酶突变的TKI耐药原代BC-CML细胞。
  • PRI-724联合尼洛替尼可显著延长注射原代BCR-ABLT315I/E255V BC-CML细胞小鼠的生存。

核心结论

  • 数据提示同时抑制β-连环蛋白与Bcr-Abl可能有助于预防或克服BC-CML中Bcr-Abl激酶依赖性或非依赖性的TKI耐药。

研究设计与样本

  • 研究采用体外细胞实验与NOD/SCID/IL2Rγ null小鼠体内实验,检测BC-CML干细胞/祖细胞中β-连环蛋白表达并评估C82或PRI-724联合尼洛替尼的效应。

主要发现

  • CyTOF分析显示β-连环蛋白在BC-CML干细胞/祖细胞中过表达,尤其在粒-巨噬祖细胞中,并在CD34+CD38+CD123hiTim-3hi亚群中最高。
  • 与间充质基质细胞共培养可诱导CML细胞中β-连环蛋白及其靶点CD44的表达。
  • C82与尼洛替尼协同杀伤KBM5T315I及伴或不伴BCR-ABL激酶突变的TKI耐药原代BC-CML细胞,即使在白血病/间充质基质细胞共培养条件下亦然。
  • 短发夹RNA沉默β-连环蛋白可恢复原代BCR-ABLT315I/E255V BC-CML细胞对尼洛替尼的敏感性。
  • PRI-724联合尼洛替尼显著延长注射原代BCR-ABLT315I/E255V BC-CML细胞小鼠的生存,联合治疗选择性靶向CML祖细胞并抑制CD44、c-Myc、survivin、p-CRKL和p-STAT5表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitor (TKI) resistance and progression to blast crisis (BC), both related to persistent β-catenin activation, remain formidable challenges for chronic myeloid leukemia (CML). We observed overexpression of β-catenin in BC-CML stem/progenitor cells, particularly in granulocyte-macrophage progenitors, and highest among a novel CD34+CD38+CD123hiTim-3hi subset as determined by CyTOF analysis. Co-culture with mesenchymal stromal cells (MSCs) induced the expression of β-catenin and its target CD44 in CML cells. A novel Wnt/β-catenin signaling modulator, C82, and nilotinib synergistically killed KBM5T315I and TKI-resistant primary BC-CML cells with or without BCR-ABL kinase mutations even under leukemia/MSC co-culture conditions. Silencing of β-catenin by short interfering RNA restored sensitivity of primary BCR-ABLT315I/E255V BC-CML cells to nilotinib. Combining the C82 pro-drug, PRI-724, with nilotinib significantly prolonged the survival of NOD/SCID/IL2Rγ null mice injected with primary BCR-ABLT315I/E255V BC-CML cells. The combined treatment selectively targeted CML progenitors and inhibited CD44, c-Myc, survivin, p-CRKL and p-STAT5 expression. In addition, pretreating primary BC-CML cells with C82, or the combination, but not with nilotinib alone, significantly impaired their engraftment potential in NOD/SCID/IL2Rγ-null-3/GM/SF mice and significantly prolonged survival. Our data suggest potential benefit of concomitant β-catenin and Bcr-Abl inhibition to prevent or overcome Bcr-Abl kinase-dependent or -independent TKI resistance in BC-CML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhou H, Mak PY, Mu H, et al. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017. PMID: 28321124. doi:10.1038/leu.2017.87

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。